MDx/CDx Focus: Epigenomics Septin9 Deal; BRCA MASTR Dx Gets CE Mark; Xalkori Phase III Study Results
June 19, 2012
MDx/CDx Focus: Epigenomics Septin9 Deal; BRCA MASTR Dx Gets CE Mark; Xalkori Phase III Study Results
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - CPTAC, Seoul National University to Test Proteomic Workflows Including MRM-MS in Clinical Setting
February 8, 2013 / ProteoMonitor - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Studies Reported At ESMO on Roche's Herceptin, T-DM1, Pfizer's Xalkori
October 3, 2012 / Pharmacogenomics Reporter - CPTAC Organizers, Researchers Offer Update on Plans and Progress as Project Data Portal Goes Live
September 21, 2012 / ProteoMonitor